Trial · NCT01263509
Adverse events60
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 60
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Nasopharyngitis | Infections and infestations | Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 38 | 108 | |
| other | Nasopharyngitis | Infections and infestations | Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 30 | 105 | |
| other | Bronchitis | Infections and infestations | Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 6 | 108 | |
| other | Bronchitis | Infections and infestations | Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 3 | 105 | |
| other | Cystitis | Infections and infestations | Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 4 | 108 | |
| other | Cystitis | Infections and infestations | Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 2 | 105 | |
| other | Pharyngitis | Infections and infestations | Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 1 | 108 | |
| other | Pharyngitis | Infections and infestations | Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 4 | 105 | |
| other | Seasonal allergy | Immune system disorders | Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 6 | 108 | |
| other | Seasonal allergy | Immune system disorders | Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 1 | 105 | |
| other | Upper respiratory tract inflammation | Respiratory, thoracic and mediastinal disorders | Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 12 | 108 | |
| other | Upper respiratory tract inflammation | Respiratory, thoracic and mediastinal disorders | Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 5 | 105 | |
| other | Diarrhoea | Gastrointestinal disorders | Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 5 | 108 | |
| other | Diarrhoea | Gastrointestinal disorders | Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 3 | 105 | |
| other | Gastritis | Gastrointestinal disorders | Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 1 | 108 | |
| other | Gastritis | Gastrointestinal disorders | Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 4 | 105 | |
| other | Abdominal distension | Gastrointestinal disorders | Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 4 | 108 | |
| other | Abdominal distension | Gastrointestinal disorders | Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 0 | 105 | |
| other | Hepatic function abnormal | Hepatobiliary disorders | Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 4 | 108 | |
| other | Hepatic function abnormal | Hepatobiliary disorders | Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 0 | 105 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01263509/events